Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, UCD, Dublin, Ireland.
Clin Immunol. 2015 Nov;161(1):2-10. doi: 10.1016/j.clim.2015.04.005. Epub 2015 Apr 28.
Rheumatic diseases, such as rheumatoid and psoriatic arthritis are systemic inflammatory conditions characterized by a chronic form of arthritis, often leading to irreversible joint damage. Early treatment for patients with rheumatic diseases is required to reduce or prevent joint injury. However, early diagnosis can be difficult and currently it is not possible to predict which individual patient will develop progressive erosive disease or who may benefit from a specific treatment according to their clinical features at presentation. Biomarkers are therefore required to enable earlier diagnosis and predict prognosis in both rheumatoid arthritis and psoriatic arthritis. In this review we will examine the evidence and current status of established and experimental biomarkers in rheumatoid and psoriatic arthritis for three important purposes; disease diagnosis, prognosis and prediction of response to therapy.
风湿性疾病，如类风湿关节炎和银屑病关节炎，是全身性炎症性疾病，其特征为慢性关节炎，常导致不可逆转的关节损伤。需要对风湿性疾病患者进行早期治疗，以减少或预防关节损伤。然而，早期诊断可能较为困难，目前根据患者的临床表现，尚无法预测哪些个体患者将发展为进行性侵蚀性疾病，或者哪些患者可能受益于特定治疗。因此，需要生物标志物来实现类风湿关节炎和银屑病关节炎的早期诊断和预后预测。在这篇综述中，我们将检查已确立和实验性生物标志物在类风湿关节炎和银屑病关节炎中的证据和现状，以达到三个重要目的：疾病诊断、预后和对治疗反应的预测。
